Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine
Authors:
Open Access
- 19 November 2013
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 2 (2) , 145-158
Abstract
The Japanese encephalitis virus (JEV) is endemic in many countries in southern Asia and the western Pacific Rim, with new spread to previously unrecognized countries. It is an important cause of childhood neurological disease associated with permanent neurological sequelae and death. Fortunately, JE is a vaccine-preventable disease. The ChimeriVax™-JE (Sanofi Pasteur, Lyon, France) is a live-attenuated chimeric vaccine derived from the live-attenuated yellow fever virus, YF17D, which expresses the envelope proteins of the attenuated JEV vaccine strain, SA14-14-2. It is a safe, well-tolerated vaccine that is highly immunogenic in adults and children. The average geometric mean neutralizing antibody titer (GMT) in adults is 1,392 and over 90% of adults remain seroprotected 5 years after vaccination. In children and toddlers, more than 80% remain seroprotected 2 years after primary vaccination and demonstrate a robust and durable anamnestic response (>500-fold rise in GMT) with 99.1% seroprotection rates 1 year after a booster vaccine dose. The ChimeriVax™-JE is effective in children living in endemic regions where the vaccine could possibly be integrated into existing childhood vaccination programs. ChimeriVax™-JE is also indicated for travelers at risk of JE infection.Keywords
This publication has 49 references indexed in Scilit:
- Estimated global incidence of Japanese encephalitis:Bulletin of the World Health Organization, 2011
- Genotype V Japanese Encephalitis Virus Is EmergingPLOS Neglected Tropical Diseases, 2011
- Japanese Encephalitis, Tibet, ChinaEmerging Infectious Diseases, 2011
- Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsThe Pediatric Infectious Disease Journal, 2010
- Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccineHuman Vaccines, 2010
- Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trialsVaccine, 2010
- Japanese Encephalitis in Travelers from Non-Endemic Countries, 1973–2008The American Journal of Tropical Medicine and Hygiene, 2010
- Japanese Encephalitis: Defining Risk Incidence for Travelers to Endemic Countries and Vaccine Prescribing From the UK and Switzerland: Table 1Journal of Travel Medicine, 2009
- Development and Evaluation of Reverse Transcription-Loop-Mediated Isothermal Amplification Assay for Rapid and Real-Time Detection of Japanese Encephalitis VirusJournal of Clinical Microbiology, 2006
- Wind-Blown Mosquitoes and Introduction of Japanese Encephalitis into AustraliaEmerging Infectious Diseases, 2001